Semaglutide-induced muscle loss completely resisted by female ob/ob mice, revealing sex-specific protection.

Pharmacological therapies like semaglutide, a GLP-1R agonist, are highly effective for inducing weight loss in obesity. However, a significant concern with GLP-1RA-induced weight reduction is the concomitant loss of skeletal muscle mass, which can account for up to 45% of total weight lost. This muscle loss can compromise long-term health, mobility, and metabolic function. Understanding factors that mitigate this adverse effect is crucial. Traditional diet-induced obesity models in C57BL/6J mice often show sex-specific differences, with females being relatively resistant to weight gain, complicating the study of sex-specific metabolic responses to interventions like semaglutide.

Researchers utilized ob/ob mice, a model of genetic obesity, to investigate sex-specific effects of semaglutide on weight loss and skeletal muscle outcomes. The study aimed to determine if semaglutide treatment produced differential effects on muscle mass and function between male and female mice. Both sexes of ob/ob mice were administered semaglutide (specific dose and duration not detailed in abstract) and their body weight, skeletal muscle mass, and muscle strength were assessed. The primary focus was on comparing the impact of semaglutide on muscle parameters between male and female cohorts.

The study revealed significant sex-specific differences in response to semaglutide treatment regarding skeletal muscle preservation. While semaglutide generally had minimal effects on overall skeletal muscle mass and strength in ob/ob mice, a striking finding emerged concerning female subjects. The abstract does not provide specific quantitative data such as percentages or p-values for muscle mass changes, but it emphasizes a qualitative outcome. This suggests that while some muscle loss might have occurred in males, it was not substantial enough to be highlighted as a primary negative effect. However, the female response was distinct and absolute.

Females were completely resistant to loss of muscle mass following semaglutide administration. This complete protection in females contrasts with the general 'minimal effects' observed, implying a potential, albeit unquantified, susceptibility in males or a robust protective mechanism unique to females. The findings underscore that semaglutide exerts sex-specific effects on muscle preservation during weight loss, necessitating further investigation into the underlying molecular mechanisms.